Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho Considers Extension of Tax Break on Research Expenses
November 9, 2009
- Takeda to Develop Global Business as “Medium-Sized Global Pharma”: Mr Hasegawa
November 9, 2009
- Japan Is Obliged to Promote Use of Generics: Dr Suzuki
November 9, 2009
- Medipal Aims at Sales of ¥30 Bil. in China in FY2012
November 9, 2009
- Dr Adachi Confirms ConservativeStance toward Industry Proposal
November 9, 2009
- Generic Amlodipine Comparable to Original Version: NPO Report
November 9, 2009
- Chuikyo Back to Work
November 9, 2009
- Daiichi Sankyo Applies for Injectable Levofloxacin on the Same Day as IP High Court Ruling
November 9, 2009
- Nissui to Launch OTC Version of Epadel in Spring 2010
November 9, 2009
- Cravit's Patent Extension Rejected by IP High Court
November 9, 2009
- OTC Drugs Market Down 1% to ¥774 Bil. in 2008: Yano Research
November 9, 2009
- Generics’Share Lowest in Japan among 15 Advanced Countries
November 9, 2009
- Kenko.com to Sell OTC Drugs On-line From Singapore
November 9, 2009
- Stroke Policy Summit Stresses the Need for Law
November 9, 2009
- R&D NEWS IN BRIEF
November 9, 2009
- Osteoporosis Treatment Effective for Glycemic Control: Prof. Sugimoto
November 9, 2009
- Korosho Invites Applications for Designation as “Global Clinical Research Centers”
November 9, 2009
- Eisai Opens Regional Office in Bahrain
November 9, 2009
- Mr Hasegawa Appointed Chairman of MLIT's Growth Strategy Council
November 2, 2009
- Korosho to Increase Financial Assistance for IFN Therapy
November 2, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…